Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia — from molecular mechanisms to clinical relevance

Raquel Alves, Ana Cristina Gonçalves, Sergio Rutella, António M. Almeida, Javier De Las Rivas, Ioannis P. Trougakos, Ana Bela Sarmento Ribeiro*

*Autor correspondente para este trabalho

Resultado de pesquisarevisão de pares

24 Citações (Scopus)
117 Transferências (Pure)

Resumo

Resistance to targeted therapies is a complex and multifactorial process that culminates in the selection of a cancer clone with the ability to evade treatment. Chronic myeloid leukemia (CML) was the first malignancy recognized to be associated with a genetic alteration, the t(9;22)(q34;q11). This translocation originates the BCR-ABL1 fusion gene, encoding the cytoplasmic chimeric BCR-ABL1 protein that displays an abnormally high tyrosine kinase activity. Although the vast majority of patients with CML respond to Imatinib, a tyrosine kinase inhibitor (TKI), resistance might occur either de novo or during treatment. In CML, the TKI resistance mechanisms are usually subdivided into BCR-ABL1-dependent and independent mechanisms. Furthermore, patients’ compliance/adherence to therapy is critical to CML management. Techniques with enhanced sensitivity like NGS and dPCR, the use of artificial intelligence (AI) techniques, and the development of mathematical modeling and computational prediction methods could reveal the underlying mechanisms of drug resistance and facilitate the design of more effective treatment strategies for improving drug efficacy in CML patients. Here we review the molecular mechanisms and other factors involved in resistance to TKIs in CML and the new methodologies to access these mechanisms, and the therapeutic approaches to circumvent TKI resistance.
Idioma originalEnglish
Número do artigo4820
Número de páginas36
RevistaCancers
Volume13
Número de emissão19
DOIs
Estado da publicaçãoPublicado - 1 out 2021

Impressão digital

Mergulhe nos tópicos de investigação de “Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia — from molecular mechanisms to clinical relevance“. Em conjunto formam uma impressão digital única.

Citação